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Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies
for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable
angina and at least 1 significant (70%) angiographic coronary stenosis who were randomly assigned to an ini-
tial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Al-
though the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other
major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subse-
quent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is
provided. (J Am Coll Cardiol 2007;50:1598–603) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.063u
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mince the introduction of coronary balloon angioplasty by
ruentzig in 1977, significant evolution has occurred in
oth catheter-based percutaneous coronary intervention
PCI) as well as adjunctive pharmacotherapies. Since bal-
oon angioplasty was supplanted by bare-metal stents
BMS), and subsequently drug-eluting stents (DES), a
eries of randomized comparative clinical trials have dem-
nstrated a progressive decline in both angiographic and
linical restenosis with each technologic iteration. However,
o discernible differences in the occurrence of death or
ecurrent myocardial infarction (MI) have been observed
uring device evolution (1–3). Similar iterative improve-
ents in medical therapy for symptomatic coronary artery
isease (e.g., lipid-lowering, antiplatelet, blood pressure,
nd diabetic therapies) have been associated with improved
linical outcomes. Although both aggressive and preemptive
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ccepted July 7, 2007.se of PCI for ST-segment elevation MI as well as early
ngiography and PCI for non–ST-segment elevation acute
oronary syndromes have been demonstrated to improve
urvival and to reduce the incidence of death or nonfatal MI
ompared with aggressive medical (nonrevascularization)
herapy alone (4–6), the prescription for performing PCI in
atients with stable symptomatic coronary stenoses has
emained limited to the relief of symptoms and improve-
ent in quality of life (7–11).
Not surprisingly (and in concert with multiple prior
tudies comparing PCI to medical therapy in stable angina
atients), the COURAGE (Clinical Outcomes Utilizing
evascularization and Aggressive Drug Evaluation) trial
eaffirms the premise that an initial management strategy of
CI using BMS does not reduce the risk of death, MI, or
ther major cardiovascular events when added to “optimal”
edical therapy compared with optimal medical therapy
lone (12). Because this observation appears to be neither
ovel nor surprising, why has it generated so much public
nd professional interest? To understand what (if any)
mplications this trial should have for current clinical prac-
ice (the “consequences”), let us first closely examine the
onstruct, execution, and observations of the COURAGE
rial (the “truth”).
Because atherosclerotic cardiovascular disease remains the
ajor cause of death and/or disability in the industrialized
orld, iterative developments in treatment strategies may
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October 16 2007:1598–603 Percutaneous Revascularization for Stable Anginaave broad public health policy implications. Currently, at least
5 million Americans self-report the presence of coronary
rtery disease, with2 million diagnostic catheterizations,1
illion PCIs (60% for unstable angina, 10% for acute MI,
nd 30% for stable angina), and 350,000 coronary artery
ypass operations performed yearly (Fig. 1) (13,14). Thus,
ecause approximately 9% get revascularized each year (7%
CI, 2% surgery), the vast majority of Americans receive
edical therapy for their coronary artery disease. Before
ttempting to extrapolate the results of the COURAGE trial
o the broader scope of clinical practice, we must first examine
he study population and the treatment(s) prescribed.
Almost 36,000 patients were screened for the COUR-
GE trial, from which 3,071 (8.6%) met eligibility criteria
nd 2,287 (6.3%) were subsequently randomized. Of the
,149 patients randomly assigned to PCI, 73 either did not
ave the procedure or had a stenosis that “could not be
ilated” and 107 were lost to follow-up. Thus, 15.7% of
atients assigned to PCI were either not treated or did not
omplete follow-up. Conversely, 97 (8.5%) of the 1,138
atients assigned to medical therapy (no initial PCI) were
ost to follow-up. Importantly, although all patients had at
east 1 coronary vessel with a proximal 70% angiographic
tenosis (almost 70% had 2-vessel disease with at least 1
essel suitable for PCI) associated with objective evidence of
yocardial ischemia, nearly 80% had minimal or no angina
Canadian Cardiovascular Society [CCS] class II or less
ith a median duration of 5 months), and left ventricular
jection fraction was well preserved (mean61%). The trial
Figure 1 Current Treatment for Coronary Artery Disease
Current treatment breakdown for 15 million Americans with self-reported coro-
nary artery disease. Roughly 9% of patients get revascularized yearly (7% percu-
taneous coronary intervention [PCI], 2% coronary artery bypass graft [CABG]).
This pool is dynamic in both composition and symptom status. Some patients
die, new patients are added, and symptoms change (from stable to unstable
and vice versa). Modified from references 13 and 14.esign prospectively specified that no more than 10% of iedically treated patients would
ross over to PCI in the first 4
ears to manage patients who
eveloped severe or progressive
ngina during follow-up (15).
High levels of compliance
ith medical therapies were ob-
erved throughout the COUR-
GE trial, and at 1, 3, and 5
ears of follow-up in the medi-
ally treated cohort compliance
ates were 95%, 95%, and 94% for aspirin, 95%, 92%, and
3% for statins, and 89%, 86%, and 86% for beta-blockers,
espectively. Approximately 70% of patients achieved a
ow-density lipoprotein level 85 mg/dl, 65% and 94% of
atients achieved systolic and diastolic blood pressure tar-
ets of 130 and 85 mm Hg, respectively, and 45% of
iabetic patients achieved a hemoglobin A1C level of
7.0%. Thus, both compliance with multiple evidence-
ased medical therapies and achievement of treatment
argets were exemplary in this trial.
In this context, several important questions arise. First,
nd foremost, are these findings new? Multiple studies and
eta-analyses have previously demonstrated that revascu-
arization by either PCI (6–11,16) or coronary bypass
urgery (17–22) does not improve the already excellent
urvival of stable angina patients on optimal medical therapy
Table 1). This lack of demonstrable benefit for reduction in
eath or nonfatal MI stands in contrast to the clear benefit
bserved following PCI (vs. medical therapy) in both
T-segment elevation and non–ST-segment elevation acute
oronary syndromes (4–6). Therefore, the “failure” of PCI
n the COURAGE trial to meet the hypothesized aggres-
ive end point of a 22% reduction in death or nonfatal MI
ompared with medical therapy alone in stable angina
atients is neither surprising nor new. Indeed, given the
eight of earlier randomized controlled clinical trial evi-
ence, a noninferiority trial design may have been more
ppropriate.
Importantly, the power analysis assumptions made by the
OURAGE trial must be closely examined. A total of
,260 patients initially were to have been enrolled to accrue
prespecified 614 primary end point events based on a
rojected 3-year rate of death or MI of 21% in patients
ssigned to medical therapy alone. During the course of the
tudy, the definition of MI was changed to include patients
ith an elevated troponin and the durations for both
andomization and follow-up were extended. Despite the
iberalized definition of MI and extended duration of
ollow-up, the observed rate of death or MI in medically
reated patients to 3 years of follow-up was only 12% (413
nd point events, or 67% of the projected requirement), so
hat the trial remains underpowered. Because patients were
nrolled after coronary angiography, those with severe
nd/or complex stenosis may not have been included, and
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CCS  Canadian
Cardiovascular Society
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary interventionnvestigator bias in patient selection toward lower angio-
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Percutaneous Revascularization for Stable Angina October 16 2007:1598–603raphic risk cannot be excluded. This premise (lower-risk
atients enrolled) would appear to be supported by the
elatively low (0.4%) annual cardiac mortality observed in
he entire study cohort. Furthermore, the use of all cause
eath in the primary end point may have obscured the
bility to differentiate between treatment strategies, because
CI would not be expected to reduce noncardiac-related
eath compared with medical therapy. Of note, only 48
eaths (26.7% of total) were confirmed to be cardiac related
n this trial. Finally, the COURAGE trial used the defini-
ion of symptoms accompanied by any creatine kinase-MB
nzyme elevation above normal to define periprocedural
PCI) MI (15). Such a broadly inclusive definition enhanced
nd point accruement but, no doubt, disadvantaged PCI
nd has little, if any, real prognostic import (23,24).
Second, was the performance of PCI optimal in this trial?
nfortunately, the absence of a formal angiographic core
aboratory analysis in the COURAGE trial makes accurate
ssessment of stenosis location and severity as well as
etermination of angiographic procedural success rates more
ifficult. In this context, operator-assessed per-lesion suc-
ess rates were only 93% and did not take into account those
atients in whom the stenosis could not be crossed or those
n whom PCI was not attempted. Considering the trial
esign and execution, it is perhaps surprising that PCI did
s well as was observed for reducing angina symptoms
versus medical therapy alone) during the first 3 years of
tudy follow-up. Despite the fact that 70% of patients
ssigned to PCI had 2-vessel disease, only 36% received
1 stent and only 2.7% were treated with a DES. Indeed,
artial and/or incomplete revascularization of patients with
ultivessel disease has repeatedly been associated with
orsened clinical outcomes (vs. complete revascularization)
25–27), particularly with an increase in the requirement for
epeat revascularization procedures. This fact may at least in
art explain the observation that 21.1% of PCI-treated
atients in the COURAGE trial required an additional
evascularization procedure at a median of 10 months of
ollow-up. We are not informed how many of these addi-
ional procedures were performed for BMS restenosis,
emaining untreated stenoses, or progression of disease that
Summaries of Trials Comparing Medical TherapyVersus PCI for St ble Coronary Artery Disease P
Table 1 Summaries of Trials Comparing MedVersus PCI for Stable Coronary Arte
Trial (Ref. #) Mortality and MI Ang
RITA-2 (7) No difference PCI
ACME (8) No difference PCI
ACME-2 (16) No difference PCI
MASS (9) No difference PCI
MASS-II (11) No difference PCI
AVERT (10) No difference PCI
TIME* No difference PCI
COURAGE (12) No difference No
*TIME Investigators. Lancet 2001;358:951–7.
MI  myocardial infarction; NA  not available; PCI  percutaneouas initially considered noncritical. These observations are wimilar to those from a recent analysis of the New York
tate Angioplasty Database, where incomplete revascular-
zation was associated with more frequent additional revas-
ularization procedures in follow-up as well as a relative
25% to 35%) increase in mortality (25).
In addition, disparity in outcomes after PCI was observed
ased on where the procedure was performed. For example,
hose patients treated outside of the U.S. Veterans Admin-
stration (VA) hospital system demonstrated a 29% relative
eduction in the primary end point (death or MI) after PCI
ompared with medical treatment alone (15% vs. 21%,
espectively). Although too few patients were enrolled
utside of the VA system to provide adequate statistical
ower for analysis, this magnitude of primary end point
eduction would satisfy the primary hypothesis of the trial.
n addition, apparent differences in the composite occur-
ence of death or MI between U.S. (21% to 22%) and
anadian (14%) patients are not explained.
The use of revascularization in the medically treated
ohort significantly clouds interpretation of a 72% “angina-
ree” status for this subgroup at 5 years, given that 43% of
hese patients began the trial with minimal (CCS class I) or
o angina and 32% were subsequently revascularized for
evere or worsening symptoms (and were counted in the
edically treated cohort by intention to treat). In this
ontext of randomized controlled trials comparing medical
herapy with PCI in stable coronary disease patients (7–11),
nly the COURAGE trial failed to observe a relative benefit
f PCI for providing long-term angina relief (Table 1) (12).
ne potential explanation for this observation is that
atients enrolled in the COURAGE trial experienced at
aseline a mean of 10 and a median of 3 anginal episodes
eekly as reported in 3 separate publications (12,15,28).
his skewed distribution suggests the presence of 2 patient
opulations and may have contributed to the higher-than-
redicted crossover rate (32%) to PCI in the more symp-
omatic subpopulation. Of note, an “erratum” revising the
ean angina frequency to 6 episodes weekly is apparently
ending publication (29).
Only 2.7% of the COURAGE trial PCI patients were
reated with a DES. The relative benefit of DES compared
ts
Therapy
sease Patients
lief QOL Repeat Revascularization
PCI PCI
PCI PCI
PCI NA
NA No difference
PCI No difference
PCI No difference
PCI PCI
nce PCI PCI
ary intervention; QOL  quality of life.atien
ical
ry Di
ina Re
differeith BMS for reducing clinically driven repeat revascular-
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October 16 2007:1598–603 Percutaneous Revascularization for Stable Anginazation (50% to 70% relative reduction) has been repeatedly
emonstrated in randomized controlled clinical trials (30–
2). The DES (compared with BMS) has provided a
arked reduction in both clinical as well as angiographic
70% to 80% relative reduction) restenosis, with no signif-
cant differences observed in the occurrences of death or
onfatal MI (3,30–32). Freedom from clinically driven
epeat revascularization is a surrogate for freedom from
ngina, improved exercise tolerance, and enhanced quality
f life. Therefore, one could reasonably predict that a
trategy of complete revascularization by PCI using DES in
he COURAGE trial would have reduced the need for
epeat revascularization procedures and would have im-
roved the angina-free symptom status of the PCI cohort.
ndeed, repeat revascularization rates to 1 year of follow-up
ave been comparable in comparisons of coronary artery
ypass surgery with multivessel PCI using DES from both
he ERACI (Argentine Randomized Study: Coronary An-
ioplasty With Stenting Versus Coronary Artery Bypass
urgery in Patients With Multiple-Vessel Disease)-II/III
nd the ARTS-II (Arterial Revascularization Therapies
tudy Part II: Sirolimus-Eluting Stents for the Treatment
f Patients With Multivessel de Novo Coronary Artery
esions) trials (33–35). These observations suggest that
omparable clinical benefit (reduction in angina and revas-
ularization) may be provided by complete PCI using DES
nd coronary bypass surgery in patients with multivessel
isease but await more definitive confirmation by ongoing
andomized controlled clinical trials such as the SYNTAX
Synergy Between PCI With Taxus and Cardiac Surgery)
36), FREEDOM (Comparison of Two Treatment for
ultivessel Coronary Artery Disease in Individuals With
iabetes) (37), CARDIA (Coronary Artery Revasculariza-
ion in Diabetes) (38), and VA CARDS (Coronary Artery
evascularization in Diabetes) (39) trials. Nevertheless,
espite the limitations of PCI as used in the COURAGE
rial, there remained a significant reduction in the require-
ent for revascularization at follow-up to a median of 4.6
ears (21.1% vs. 32.6%; p  0.001), as well as improvement
n quality of life accompanied by a reduction in perceived
hysical limitation and angina frequency in those patients
nitially assigned to PCI compared with medical therapy
lone (12,40). In this context, a 13% relative reduction in
ortality to 4.6 years of follow-up was observed after an
nitial PCI strategy.
Finally, are the results of optimal medical therapy as
chieved in the COURAGE trial applicable to general
linical practice? The COURAGE trial investigators and
atients are to be commended for exemplary compliance
ith medical therapies. However, recent registry data sug-
est that medical compliance, particularly with multiple
oncomitant medications is considerably less in the “real
orld” than was observed in the COURAGE trial. Indeed,
t 1 year of follow-up, 90% or more of the medically
reated cohort in COURAGE was compliant with aspirin,
tatin, and beta-blocker therapies. This level of protocol- wriven polypharmaceutic compliance stands in contrast with
report from the CRUSADE (Can Rapid Risk Stratifica-
ion of Unstable Angina Patients Suppress Adverse Out-
omes With Early Implementation of the American College
f Cardiology/American Heart Association Guidelines)
egistry, where 46% of patients were compliant with beta-
locker alone, 36% with beta-blocker plus aspirin, and only
1% with beta-blocker, aspirin, plus lipid-lowering therapy
n combination (41). Thus, beta-blocker therapy compli-
nce rates of86% through 3 years of follow-up as observed
n the COURAGE trial appear to be uncommon in clinical
ractice. A recent “real-world” international registry re-
orted that 30% of medically managed patients with docu-
ented coronary artery disease received no lipid-lowering
herapy and that compliance with guideline-recommended
edical treatment was greater in patients with prior revas-
ularization (PCI or coronary artery bypass graft) (42).
urthermore, medical noncompliance in clinical practice has
een associated with increased mortality in late follow-up
43). Thus, the high rates of medical compliance as well as
reatment to target levels for cholesterol, blood pressure, and
lucose achieved in the COURAGE trial are exemplary but
re not commonly reported from clinical practice registries.
n this regard, clinical research nurse coordinators may
rovide a “case management” function not often available
utside the confines of a randomized controlled clinical trial.
OURAGE in Perspective
hat message(s) should the clinical practitioner derive from
he COURAGE trial? First, in the context of precedent
ata (7–11) the COURAGE trial set an unrealistic goal: to
how a 22% reduction in the already low annual rates of
eath and MI observed on aggressive medical therapy in
table coronary artery disease patients. The COURAGE
rial does demonstrate a significantly better angina-free
tatus as well as a reduction in the requirement for subse-
uent revascularization in those patients initially treated
ith PCI compared with medical therapy alone. Further-
ore, these benefits were accrued by the PCI cohort with
o penalty in terms of increased rates of death or MI.
econd, the COURAGE trial appears to confirm earlier
bservations that incomplete revascularization of patients
ith multivessel disease may be associated with lesser
egrees of clinical benefit and more frequent requirements
or repeat revascularization (25–27). Third, despite “opti-
al” and possibly “unrealistic” (as applied in routine clinical
ractice) intensive medical therapy for stable coronary dis-
ase patients, severe or progressive anginal symptoms led to
surprisingly high rate (32%) of “crossover” to revascular-
zation in patients initially assigned to medical therapy alone
no PCI). Fourth, the potential clinical benefits from DES
ombined with more complete coronary revascularization in
ultivessel disease patients would likely further enhance the
agnitude and duration of antianginal benefit associated
ith the initial PCI strategy from what was observed in the
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Percutaneous Revascularization for Stable Angina October 16 2007:1598–603OURAGE trial. Fifth, because enrollment into the
OURAGE trial occurred after coronary angiography and
efinition of the coronary anatomy, this valuable diagnostic
nd prognostic modality (angiography) should not be de-
ied to patients with stable angina pectoris. Finally, medical
nd catheter-based therapies play at least complementary if
ot synergistic roles in the treatment of patients with
therosclerotic cardiovascular disease. The choice of thera-
y(s) for each individual patient must be made based on
oronary anatomic suitability and in the context of the
atient’s lifestyle, functional capacity, level of symptom
imitation, and their ability (physically, emotionally, and
nancially) to take the prescribed treatment. If PCI revas-
ularization is performed, this procedure should be done
sing the most complete and effective tools and always in
ddition to (rather than in place of) medical therapies that
educe plaque progression.
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